Company Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications.
The company is headquartered in Boston, Massachusetts.
Country | United States |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 93 |
CEO | Dr. Paula Ragan Ph.D. |
Contact Details
Address: 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 United States | |
Phone | 857-529-8300 |
Website | x4pharma.com |
Stock Details
Ticker Symbol | XFOR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001501697 |
CUSIP Number | 98420X103 |
ISIN Number | US98420X1037 |
Employer ID | 27-3181608 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Paula Ragan Ph.D. | Chief Executive Officer, President and Director |
Adam S. Mostafa | Chief Financial Officer, Treasurer and Corporate Secretary |
Dr. Mary DiBiase Ph.D. | Chief Operating Officer |
Dr. Richard Peters M.D., Ph.D. | Founder |
Dr. Renato T. Skerlj Ph.D. | Founder |
Dr. Keith T. Flaherty M.D. | Founder and Member of Corporate Advisory Board |
Dr. Arthur Taveras Ph.D. | Chief Scientific Officer |
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Vice President of Investor Relations and Corporate Communications |
Dr. Robert David Arbeit | Senior Vice President of Clinical Development and Translational Research |
Mark Baldry M.B.A. | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 19, 2024 | 8-K | Current Report |
Jun 27, 2024 | 8-K | Current Report |
Jun 11, 2024 | 8-K | Current Report |
May 22, 2024 | 8-K | Current Report |
May 9, 2024 | 8-K | Current Report |
May 7, 2024 | 10-Q | Quarterly Report |
May 7, 2024 | 8-K | Current Report |
Apr 29, 2024 | ARS | Filing |
Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 29, 2024 | DEF 14A | Other definitive proxy statements |